|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's Range||8.07 - 8.89|
|52 Week Range||4.61 - 27.74|
|Beta (5Y Monthly)||1.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan 09, 2023 - Jan 13, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.93|
Subscribe to Yahoo Finance Plus to view Fair Value for ACCD
Accolade, Inc. (Nasdaq: ACCD), which provides millions of people and their families with Personalized Healthcare, will address removing barriers to equitable healthcare as a Health Equity Impact Champion sponsor at HLTH 2022. In addition, LGBTQIA+ affirming care company, FOLX Health, joins Accolade's Trusted Partner Ecosystem, availing high-quality, integrated care for this marginalized population to Accolade 's 700+ commercial and government customers to serve their 11 million members.
While it may not be enough for some shareholders, we think it is good to see the Accolade, Inc. ( NASDAQ:ACCD ) share...
Accolade Inc (NASDAQ: ACCD) reported Q2 FY23 sales of $87.6 million, up 20% Y/Y, beating the consensus of $82.86 million and the management guidance of $82-$83.5 million. "Importantly, this is also our first full year selling our broader integrated services, and we are receiving strong validation from both new and current customers that our integrated portfolio is the right approach," said Rajeev Singh, Accolade CEO. The adjusted EBITDA loss came at $(13.7) million, better than $(19.4) million a